ReviewJournal of fungi (Basel, Switzerland)2021
Antifungal Resistance among Less Prevalent
Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Urinary tract infection caused by rare yeastFrontiers in immunology · 2026Review
- Article
- Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
- Impact of Biofilm Formation by VaginalJournal of fungi (Basel, Switzerland) · 2025Article
- Overcoming antifungal resistance inFrontiers in cellular and infection microbiology · 2025Review
- A Mini-Review of In Vitro Data forJournal of fungi (Basel, Switzerland) · 2024Review
- Antifungal Susceptibility ofPathogens (Basel, Switzerland) · 2024Article
- Candida albicans and Antifungal Peptides.Infectious diseases and therapy · 2023Article
- Exposure ofPathogens (Basel, Switzerland) · 2023Article
- Distribution and antifungal susceptibility profiles of Candida species isolated from people living with HIV/AIDS in a public hospital in Goiânia, GO, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022Article
- Synthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives.Pharmaceutics · 2022Article
- Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three NonprevalentAntimicrobial agents and chemotherapy · 2021Article
- The Mould War: Developing an Armamentarium against Fungal Pathogens Utilising Thymoquinone, Ocimene, and Miramistin within Bacterial Cellulose Matrices.Materials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal diseases and antifungal resistance continue to increase, including those caused by rare or emerging species. However, the majority of the published in vitro susceptibility data are for the most common fungal species. We reviewed the literature in order to pool reference minimal inhibitory concentration (MIC) data (Clinical and Laboratory Standards Institute-CLSI and European Committee on Antimicrobial Susceptibility-EUCAST) for rare/non-prevalent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.